Your AI-Trained Oncology Knowledge Connection!
Amultihistology basket study proved the targetability of the <em>AKT1 E17K</em> mutation in human cancers by treating patients with various types of cancer harboring an <em>AKT1 E17K </em>mutation with AZD5363, an oral pan-AKT inhibitor, according to findings published in the <em>Journal of Clinical Oncology</em>.
Corey Langer, MD, provides details on the goals and implications of the KEYNOTE-021 trial. Moreover, he discusses the current arena in NSCLC treatment and the obstacles that remain in treating patients without driver mutations effectively.
Russell Berman, MD, discusses ongoing surgical advances in the treatment of melanoma.
Published: July 25th 2017 | Updated:
Published: September 1st 2017 | Updated:
Published: November 7th 2017 | Updated:
